MATEON THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS
August 17, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN), a leading developer of TGF-β therapeutics, announced financial results for the second quarter ended June...
MATEON ANNOUNCES $2 MILLION FINANCING WITH GOLDEN MOUNTAIN PARTNERS TO CONDUCT CLINICAL TRIAL OF OT-101 AGAINST COVID19
June 29, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announces it has secured a $2 million in debt financing with Golden...
MATEON AND GMP COMPLETED RESEARCH AND SERVICE AGREEMENT
June 22, 2020 08:00 ET
|
Mateon Therapeutics, Inc.
- Mateon and GMP to proceed to clinical development of OT-101 and Artemisin and other antisense drug candidates against COVID-19 AGOURA HILLS, Calif., June 22, 2020 (GLOBE NEWSWIRE) --...